Sugi Predict

Sugi Predict / Targets / NSD2

NSD2

Histone-lysine N-methyltransferase NSD2 · O96028 · NSD2 on Sugi Atlas →

93,719 patent compounds predicted against NSD2, 61,823 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL147103 SCHEMBL147103 0.56 10/20
SCHEMBL109003 SCHEMBL109003 0.43 8/20
Sinefungin Sinefungin (SCHEMBL167609) 1.00 7/20
SCHEMBL38143 SCHEMBL38143 0.43 6/20
SCHEMBL97602 SCHEMBL97602 0.56 5/20
SCHEMBL119489 SCHEMBL119489 0.56 5/20
SCHEMBL154124 SCHEMBL154124 1.00 4/20
SCHEMBL140322 SCHEMBL140322 0.84 4/20
SCHEMBL151762 SCHEMBL151762 0.58 4/20
Adefovir Adefovir (SCHEMBL49373) 0.54 4/20
SCHEMBL118229 SCHEMBL118229 0.47 4/20
SCHEMBL8148 SCHEMBL8148 0.45 4/20
SCHEMBL18844 SCHEMBL18844 0.39 4/20
Mitoxantrone Mitoxantrone (SCHEMBL3000) 1.00 3/20
Mitoxantrone Mitoxantrone (SCHEMBL3928) 0.97 3/20
Mitoxantrone Mitoxantrone (SCHEMBL66384) 0.97 3/20
Mitoxantrone Mitoxantrone (SCHEMBL119801) 0.86 3/20
SCHEMBL95173 SCHEMBL95173 0.82 3/20
SCHEMBL156692 SCHEMBL156692 0.76 3/20
Ademetionine Ademetionine (SCHEMBL25177) 0.71 3/20

Clinical trials — most relevant to NSD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC PHASE3UNKNOWN
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML PHASE1/PHASE2COMPLETED
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes PHASE2COMPLETED
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias PHASE1WITHDRAWN
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease PHASE1RECRUITING
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction PHASE1WITHDRAWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
COPENHAGEN Minipuberty Study nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NSD2 binder may also engage these)

ProteinNameSimilarity
Q8BVE8 — 0.996 Q8BVE8 →
NSD3 Histone-lysine N-methyltransferase NSD3 0.988 landscape →
Q0VEE6 — 0.987 Q0VEE6 →
Q92613 — 0.987 Q92613 →
Q8N4X5 — 0.986 Q8N4X5 →
Q62315 — 0.986 Q62315 →
Q14865 — 0.985 Q14865 →
Q8BHZ4 — 0.985 Q8BHZ4 →
Q7TP65 — 0.985 Q7TP65 →
Q66T72 — 0.985 Q66T72 →
Q812D1 — 0.985 Q812D1 →
KDM3A Lysine-specific demethylase 3A 0.984 landscape →
Q6PCM1 — 0.984 Q6PCM1 →
Q92833 — 0.984 Q92833 →
Q80Y19 — 0.984 Q80Y19 →
Q09YG9 — 0.983 Q09YG9 →
Q3UWM4 — 0.983 Q3UWM4 →
B1H224 — 0.983 B1H224 →
KAT2B Histone acetyltransferase KAT2B 0.983 landscape →
Q7Z7J5 — 0.983 Q7Z7J5 →
Q8C0R0 — 0.983 Q8C0R0 →
Q8S4P6 — 0.983 Q8S4P6 →
Q17R10 — 0.983 Q17R10 →
Q8BM75 — 0.983 Q8BM75 →
KDM7A Lysine-specific demethylase 7A 0.983 landscape →
Q6IE81 — 0.983 Q6IE81 →
Q8BZ05 — 0.983 Q8BZ05 →
Q9Y4F4 — 0.982 Q9Y4F4 →
G3V8T1 — 0.982 G3V8T1 →
A0M8T5 — 0.982 A0M8T5 →